Inhibition of collagen gene expression in systemic sclerosis dermal fibroblasts by mithramycin

Annals of the Rheumatic Diseases

Volumn 64, Issue 12, 2005, Pages 1685-1691

  Sandorfi, N ^b   Louneva, N ^b   Hitraya, E ^b,d   Hajnoczky, G ^b   Saitta, B ^b,c   Jimenez, S A ^a,b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c Laboratory of Molecular and Cellular Biology of Hematopoiesis   (United States)

^d GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 1; MESSENGER RNA; MITHRAMYCIN;

ARTICLE; CELL VIABILITY; COLLAGEN SYNTHESIS; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; FIBROBLAST CULTURE; FLUORESCENCE; GENE EXPRESSION; GENETIC STABILITY; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; METABOLISM; NORTHERN BLOTTING; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RNA STABILITY; SKIN FIBROBLAST; SYSTEMIC SCLEROSIS;

BLOTTING, NORTHERN; CELL SURVIVAL; CELLS, CULTURED; COLLAGEN TYPE I; FIBROBLASTS; GENE EXPRESSION REGULATION; HUMANS; MICROSCOPY, CONFOCAL; PLICAMYCIN; PROTEIN SYNTHESIS INHIBITORS; RNA, MESSENGER; SCLERODERMA, SYSTEMIC; SKIN;

EID: 27944507214     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2005.037515     Document Type: Article

References (23)

1. Medsger TA Jr. Systemic sclerosis (scleroderma): clinical aspects. In: McCarty DJ, Koopman WJ, eds. Arthritis and allied conditions. Baltimore: Williams and Wilkins, 1997:1433-63.
2. Wigley FM. Systemic sclerosis. In: Klippel JH, Dieppe PA, eds. Rheumatology. London: Mosby, 1998:9.1-14.
3. Jimenez SA, Derk CT. Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis. Ann Intern Med 2004;140:37-50.
4. Jimenez SA, Saitta B. Alterations in the regulation of expression of the α1(I) collagen gene (COL1A1) in systemic sclerosis (scleroderma). Springer Semin Immunopathol 1999;21:397-414.
5. Hitraya EG, Jimenez SA. Transcriptional activation of the α1(I) procollagen gene in systemic sclerosis dermal fibroblasts. Role of intronic sequences. Arthritis Rheum 1996;39:1347-54.
6. Eckes B, Mauch C, Huppe G, Krieg T. Differential regulation of transcription and transcript stability of pro-alpha 1(I) collagen and fibronectin in activated fibroblasts derived from patients with systemic scleroderma. Biochem J 1996;315:549-54.
7. Hitraya EG, Varga J, Artlett CM, Jimenez SA. Identification of elements in the promoter region of the α1(I) procollagen gene involved in its up-regulated expression in systemic sclerosis. Arthritis Rheum 1998;41:2048-58.
8. Ihn H, Tamaki K. Increased phosphorylation of transcription factor Sp1 in scleroderma fibroblasts. Arthritis Rheum 2000;43:2240-7.
9. Chiang S-Y, Azizkhan JC, Beerman TA. A comparison of DNA-binding drugs as inhibitors of E2F1- and Sp1-DNA complexes and associated gene expression. Biochemistry 1998;37:3109-15.
10. Hamalainen L, Oikarinen J, Kivirikko KI. Synthesis and degradation of type I procollagen mRNAs in cultured human skin fibroblasts and the effect of cortisol. J Biol Chem 1985;260:720-5.
11. Diaz A, Jimenez SA Interferon-gamma regulates collagen and fibronectin gene expression by transcriptional and post-transcriptional mechanisms. Int J Biochem Cell Biol 1997;29:251-60.
12. Gaidarova S, Jimenez SA. Inhibition of basal and transforming growth factor-β-induced stimulation of COL1A1 transcription by the DNA intercolators, mitoxantrone and WP631 in cultured human dermal fibroblasts. J Biol Chem 2002;277:38737-45, (E-pub July 2002).
13. Szalai G, Krishnamurthy R, Hajnoczky G. Apoptosis driven by IP(3)-linked mitochondrial calcium signals. EMBO J 1999;18:6349-61.
14. Jimenez SA, Varga J, Olsen A, Li L, Diaz A, Herhal J, et al. Functional analysis of human α1(I) procollagen gene promoter: differential activity in collagen-producing and non-producing cells and response to transforming growth factor-β1. J Biol Chem 1994;269:12684-91.
15. Lewin B, ed. Genes. Oxford, New York: Oxford University Press, 1997:391-426.
16. Vigneswaran N, Mayfield CA, Rodu B, James R, Kim H-G, Miller DM. Influence of GC and AT specific DNA minor groove binding drugs on intermolecular triplex formation in the human c-Ki-ras promoter. Biochemistry 1996;35:1106-14.
17. Campbell VW, David D, Thomas S, Jones D, Roesel J, Tran-Patterson R, et al. The G-C specific DMA binding drug, mithramycin, selectively inhibits transcription of the C-myc and C-Ha-ras genes in regenerating liver. Am J Med Sci 1994;307:167-72.
18. Ray R, Snyder RC, Thomas S, Koller CA, Miller DM. Mithramycin blocks protein binding and function of the SV40 early promoter. J Clin Invest 1989;83:2003-7.
19. Hardenbol P, Van Dyke MW. In vitro inhibition of C-myc transcription by mithramycin. Biochem Biophys Res Commun 1992;185:553-8.
20. Chen S-J, Chen Y-F, Miller DM, Li H, Oparil S. Mithramycin inhibits myointimal proliferation after balloon injury of the rat carotid artery in vivo. Circulation 1994;90:2468-73.
21. Nehls MC, Brenner DA, Gruss H-J, Dierbach H, Mertelsmann R, Herrmann F. Mithramycin selectively inhibits collagen-α1(I) gene expression in human fibroblast J Clin Invest 1993;92:2916-21.
22. [Retraction in J Clin Invest 2003;112:1265.]
23. Jackson SP, Tjian R. O-Glycosylation of eukaryotic transcription factors: implications for mechanisms or transcriptional regulation. Cell 1988;55:125-33.